Table 3.

Results of the base-case analysis over a lifetime horizon^a

	Total discounted costs (£)	Total discounted QALYs	Incremental costs (£)	Incremental QALYs	ICER (£/QALY)
Fulvestrant	49,430.86	3.23
Anastrozole	30,564.12	2.68	18,866.74	0.55	34,109.49
Letrozole	26,333.82	2.46	23,097.04	0.77	29,826.63
Tamoxifen	32,300.02	2.47	17,130.83	0.76	22,532.36

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year

^aCosts are in 2016 British pounds sterling